Picture loading failed.

Pre-made Indusatumab Vedotin benchmark antibody (Whole mAb ADC, anti-GUCY2C therapeutic antibody, Anti-DIAR6/GC-C/GUC2C/MECILIL/STAR Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Indusatumab vedotin (MLN-264) is an antibody-drug conjugate that is under development for the treatment of pancreatic cancer[1] and other gastrointestinal cancers.[2] It consists of a monoclonal antibody (indusatumab) that targets the enzyme guanylate cyclase 2C which is present in some cancers, linked to an average of three to four molecules of the chemotherapeutic agent monomethyl auristatin E (MMAE).[3]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-866-1mg 1mg 4635
GMP-Bios-INN-866-10mg 10mg Inquiry
GMP-Bios-INN-866-100mg 100mg Inquiry
GMP-Bios-INN-866-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Indusatumab Vedotin Biosimilar, Whole Mab Adc, Anti-Gucy2C Antibody: Anti-DIAR6/GC-C/GUC2C/MECILIL/STAR therapeutic antibody Drug Conjugate
INN Name Indusatumab Vedotin
FormatWhole mAb ADC
Species Reactivityhuman
CH1 IsotypeIgG1 - kappa
VD LCIgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesMillennium Pharmaceuticals Inc. (Cambridge MA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0